Anamaria-Vlăduța Tomoiagă
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anamaria-Vlăduța Tomoiagă has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Cezara-Andreea Gerdanovics
Department of Internal Medicine, 4th Medical Discipline, “Iuliu Hațieganu” University of Medicine and Pharmacy, 400015 Cluj-Napoca, Romania
5 shared publications - Mircea Vasile Milaciu
Department of Internal Medicine, 4th Medical Discipline, “Iuliu Hațieganu” University of Medicine and Pharmacy, 400015 Cluj-Napoca, Romania
5 shared publications - Olga Hilda Orasan
Department of Internal Medicine, 4th Medical Discipline, “Iuliu Hațieganu” University of Medicine and Pharmacy, 400015 Cluj-Napoca, Romania
5 shared publications - Angela Cozma
Department of Internal Medicine, 4th Medical Discipline, “Iuliu Hațieganu” University of Medicine and Pharmacy, 400015 Cluj-Napoca, Romania
4 shared publications - Mirela-Georgiana Perne
Department of Internal Medicine, 4th Medical Discipline, “Iuliu Hațieganu” University of Medicine and Pharmacy, 400015 Cluj-Napoca, Romania
4 shared publications - Teodora Gabriela Alexescu
Department of Internal Medicine, 4th Medical Discipline, “Iuliu Hațieganu” University of Medicine and Pharmacy, 400015 Cluj-Napoca, Romania
4 shared publications
Latest Publications
- Open Access
- 9 October 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (20) , 3273
Vascular Phenotyping Across the CKM Syndrome: Arterial Stiffness and Endothelial Function Testing, Prognostic Value and Clinical Implementation
Cardiovascular–kidney–metabolic (CKM) syndrome represents a continuum of metabolic, renal, and cardiovascular abnormalities in which vascular dysfunction may develop before clinically overt cardiovascular disease. Endothelial dysfunction, arterial stiffness, microvascular abnormalities, and structural vascular damage may therefore provide complementary information regarding vascular injury across CKM stages. This narrative review synthesizes current evidence on the pathophysiological basis, non-invasive assessment, prognostic value, and clinical implementation of vascular phenotyping across the CKM spectrum, with particular emphasis on arterial stiffness and endothelial function. The principal approaches discussed include carotid–femoral pulse wave velocity (cfPWV), brachial–ankle pulse wave velocity, flow-mediated dilation (FMD), peripheral arterial tonometry, microvascular techniques, and structural markers such as coronary artery calcium (CAC) and carotid plaque, considered in the context of contemporary CKM staging and PREVENT-based risk assessment. Among functional vascular measures, cfPWV remains the best-validated non-invasive marker of aortic stiffness and is independently associated with cardiovascular and renal outcomes, whereas FMD provides complementary information on conduit-artery endothelial function but is limited by technical requirements and inconsistent incremental predictive value. Microvascular and glycocalyx-based techniques remain less standardized, while structural phenotyping, particularly CAC and carotid plaque assessment, has stronger evidence for risk reclassification in selected populations. Vascular phenotyping should therefore be regarded as a selective, risk-adapted strategy rather than a universal screening approach. Its greatest potential may lie in integrating vascular measures with CKM stage, PREVENT estimates, kidney and cardiac biomarkers, and structural imaging to identify disproportionate or subclinical vascular injury, particularly during progression from CKM stage 2 to stage 3. Prospective studies are needed to determine whether such multimodal phenotyping improves therapeutic decision-making and cardiovascular and kidney outcomes.
- 9 October 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (20) , 3273
Open AccessVascular Phenotyping Across the CKM Syndrome: Arterial Stiffness and Endothelial Function Testing, Prognostic Value and Clinical Implementation
Cardiovascular–kidney–metabolic (CKM) syndrome represents a continuum of metabolic, renal, and cardiovascular abnormalities in which vascular dysfunction may develop before clinically overt cardiovascular disease. Endothelial dysfunction, arterial stiffness, microvascular abnormalities, and structural vascular damage may therefore provide complementary information regarding vascular injury across CKM stages. This narrative review synthesizes current evidence on the pathophysiological basis, non-invasive assessment, prognostic value, and clinical implementation of vascular phenotyping across the CKM spectrum, with particular emphasis on arterial stiffness and endothelial function. The principal approaches discussed include carotid–femoral pulse wave velocity (cfPWV), brachial–ankle pulse wave velocity, flow-mediated dilation (FMD), peripheral arterial tonometry, microvascular techniques, and structural markers such as coronary artery calcium (CAC) and carotid plaque, considered in the context of contemporary CKM staging and PREVENT-based risk assessment. Among functional vascular measures, cfPWV remains the best-validated non-invasive marker of aortic stiffness and is independently associated with cardiovascular and renal outcomes, whereas FMD provides complementary information on conduit-artery endothelial function but is limited by technical requirements and inconsistent incremental predictive value. Microvascular and glycocalyx-based techniques remain less standardized, while structural phenotyping, particularly CAC and carotid plaque assessment, has stronger evidence for risk reclassification in selected populations. Vascular phenotyping should therefore be regarded as a selective, risk-adapted strategy rather than a universal screening approach. Its greatest potential may lie in integrating vascular measures with CKM stage, PREVENT estimates, kidney and cardiac biomarkers, and structural imaging to identify disproportionate or subclinical vascular injury, particularly during progression from CKM stage 2 to stage 3. Prospective studies are needed to determine whether such multimodal phenotyping improves therapeutic decision-making and cardiovascular and kidney outcomes.
- Open Access
- 18 July 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (14) , 2245
Stenosing Ileal Angiosarcoma Presenting as Subocclusive Syndrome: A Rare Case Report and Literature Review
Introduction: Angiosarcomas are rare malignant vascular tumors. Primary angiosarcoma of the ileum is extremely uncommon, with few cases reported in the literature. Case Report: We report the case of a 54-year-old woman who presented with abdominal pain and constipation. Endoscopic evaluation did not reveal a mass in the distal ileum; however, MRI identified a distal ileal stenosis, raising suspicion for Crohn’s disease. Surgical resection was performed, and histopathological analysis confirmed the diagnosis of primary ileal angiosarcoma. Postoperative chemotherapy was attempted but not tolerated, and the patient subsequently developed suspected peritoneal progression approximately six months after surgery. Discussion: Due to its rarity and nonspecific symptoms, ileal angiosarcoma is often diagnosed late. Imaging may suggest a vascular tumor, but definitive diagnosis requires histopathological and immunohistochemical analysis. Prognosis is generally poor, with high metastatic potential. Conclusions: This case highlights the diagnostic challenges of ileal angiosarcoma, a very rare type of tumor of the small bowel.
- 18 July 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (14) , 2245
Open AccessStenosing Ileal Angiosarcoma Presenting as Subocclusive Syndrome: A Rare Case Report and Literature Review
Introduction: Angiosarcomas are rare malignant vascular tumors. Primary angiosarcoma of the ileum is extremely uncommon, with few cases reported in the literature. Case Report: We report the case of a 54-year-old woman who presented with abdominal pain and constipation. Endoscopic evaluation did not reveal a mass in the distal ileum; however, MRI identified a distal ileal stenosis, raising suspicion for Crohn’s disease. Surgical resection was performed, and histopathological analysis confirmed the diagnosis of primary ileal angiosarcoma. Postoperative chemotherapy was attempted but not tolerated, and the patient subsequently developed suspected peritoneal progression approximately six months after surgery. Discussion: Due to its rarity and nonspecific symptoms, ileal angiosarcoma is often diagnosed late. Imaging may suggest a vascular tumor, but definitive diagnosis requires histopathological and immunohistochemical analysis. Prognosis is generally poor, with high metastatic potential. Conclusions: This case highlights the diagnostic challenges of ileal angiosarcoma, a very rare type of tumor of the small bowel.
- Open Access
- 15 July 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (14) , 2207
Renal Metastasis from Extrahepatic Cholangiocarcinoma Mimicking Renal Infarction: A Case Report and Literature Review
Background: Cholangiocarcinoma (CCA) is a rare and aggressive malignancy of the biliary tree. Renal metastasis represents an exceptionally rare event, reported in fewer than 0.5% of cases. Its clinical and imaging presentation may closely mimic benign renal conditions, particularly renal infarction, posing a significant diagnostic challenge. Case Presentation: We report the case of a 72-year-old man who initially presented with intense right-sided flank pain without urinary symptoms. Combined imaging findings, including absent Doppler signal on ultrasound and absent contrast uptake on contrast-enhanced ultrasound (CEUS) in two-thirds of the right renal parenchyma, led to an initial diagnosis of right renal infarction. Seven months later, re-evaluation prompted by macroscopic haematuria, significant weight loss, cholestatic syndrome, and markedly elevated CA 19-9 revealed an invasive renal tumour mass associated with biliary ductal dilatation. Renal biopsy with immunohistochemical analysis (CK7+, PAX8−, c-kit weakly positive) confirmed renal metastasis from extrahepatic cholangiocarcinoma. The patient’s clinical course was complicated by acute cholangitis, Clostridioides difficile enterocolitis, and upper gastrointestinal haemorrhage, requiring endoscopic retrograde cholangiopancreatography (ERCP) with biliary stenting, endoscopic ultrasound (EUS)-guided hepaticogastrostomy, and endoscopic haemostasis. Conclusions: A systematic review of the published literature identified only two previous dedicated case reports of renal metastasis from CCA, making this, to our knowledge, the third such case and the first involving an extrahepatic primary tumour presenting through its renal metastasis. This case highlights the diagnostic pitfall of mistaking hypovascular renal metastasis for renal infarction, the indispensable role of immunohistochemistry, and the importance of early percutaneous biopsy in avascular renal lesions without a confirmed thromboembolic aetiology.
- 15 July 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (14) , 2207
Open AccessRenal Metastasis from Extrahepatic Cholangiocarcinoma Mimicking Renal Infarction: A Case Report and Literature Review
Background: Cholangiocarcinoma (CCA) is a rare and aggressive malignancy of the biliary tree. Renal metastasis represents an exceptionally rare event, reported in fewer than 0.5% of cases. Its clinical and imaging presentation may closely mimic benign renal conditions, particularly renal infarction, posing a significant diagnostic challenge. Case Presentation: We report the case of a 72-year-old man who initially presented with intense right-sided flank pain without urinary symptoms. Combined imaging findings, including absent Doppler signal on ultrasound and absent contrast uptake on contrast-enhanced ultrasound (CEUS) in two-thirds of the right renal parenchyma, led to an initial diagnosis of right renal infarction. Seven months later, re-evaluation prompted by macroscopic haematuria, significant weight loss, cholestatic syndrome, and markedly elevated CA 19-9 revealed an invasive renal tumour mass associated with biliary ductal dilatation. Renal biopsy with immunohistochemical analysis (CK7+, PAX8−, c-kit weakly positive) confirmed renal metastasis from extrahepatic cholangiocarcinoma. The patient’s clinical course was complicated by acute cholangitis, Clostridioides difficile enterocolitis, and upper gastrointestinal haemorrhage, requiring endoscopic retrograde cholangiopancreatography (ERCP) with biliary stenting, endoscopic ultrasound (EUS)-guided hepaticogastrostomy, and endoscopic haemostasis. Conclusions: A systematic review of the published literature identified only two previous dedicated case reports of renal metastasis from CCA, making this, to our knowledge, the third such case and the first involving an extrahepatic primary tumour presenting through its renal metastasis. This case highlights the diagnostic pitfall of mistaking hypovascular renal metastasis for renal infarction, the indispensable role of immunohistochemistry, and the importance of early percutaneous biopsy in avascular renal lesions without a confirmed thromboembolic aetiology.
- Open Access
- 2 July 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (13) , 2081
Iron Metabolism in the Colorectal Tumor Microenvironment: Current Evidence and Clinical Implications
Iron is essential for normal cellular function, but its dysregulation is increasingly recognized as a key factor in colorectal tumorigenesis. This review provides an integrated overview of iron-related biomarkers across the full spectrum of colorectal neoplasia, from preneoplastic lesions to advanced colorectal cancer (CRC). Evidence suggests that alterations in iron metabolism begin early, at the level of colorectal adenomas, where increased iron uptake and impaired export contribute to local iron accumulation and oxidative stress. As lesions progress to carcinoma, this imbalance becomes more pronounced, leading to expansion of the intracellular labile iron pool and supporting tumor growth, metabolic adaptation, and genomic instability. At the systemic level, patients often exhibit reduced circulating iron despite preserved or elevated ferritin levels, reflecting inflammation-driven functional iron deficiency. This pattern is largely mediated by dysregulation of the hepcidin–ferroportin axis. In this context, transferrin saturation and soluble transferrin receptor may provide a more accurate assessment of iron availability than ferritin alone. At the tissue level, increased expression of iron import proteins and impaired iron export promote intracellular iron retention. Excess iron further contributes to reactive oxygen species generation, leading to damage of DNA, lipids, and proteins. Clinically, iron-related biomarkers show variable diagnostic performance but may offer prognostic value. Integrating systemic and tissue biomarkers could improve risk stratification and support personalized approaches across the CRC continuum.
- 2 July 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (13) , 2081
Open AccessIron Metabolism in the Colorectal Tumor Microenvironment: Current Evidence and Clinical Implications
Iron is essential for normal cellular function, but its dysregulation is increasingly recognized as a key factor in colorectal tumorigenesis. This review provides an integrated overview of iron-related biomarkers across the full spectrum of colorectal neoplasia, from preneoplastic lesions to advanced colorectal cancer (CRC). Evidence suggests that alterations in iron metabolism begin early, at the level of colorectal adenomas, where increased iron uptake and impaired export contribute to local iron accumulation and oxidative stress. As lesions progress to carcinoma, this imbalance becomes more pronounced, leading to expansion of the intracellular labile iron pool and supporting tumor growth, metabolic adaptation, and genomic instability. At the systemic level, patients often exhibit reduced circulating iron despite preserved or elevated ferritin levels, reflecting inflammation-driven functional iron deficiency. This pattern is largely mediated by dysregulation of the hepcidin–ferroportin axis. In this context, transferrin saturation and soluble transferrin receptor may provide a more accurate assessment of iron availability than ferritin alone. At the tissue level, increased expression of iron import proteins and impaired iron export promote intracellular iron retention. Excess iron further contributes to reactive oxygen species generation, leading to damage of DNA, lipids, and proteins. Clinically, iron-related biomarkers show variable diagnostic performance but may offer prognostic value. Integrating systemic and tissue biomarkers could improve risk stratification and support personalized approaches across the CRC continuum.
- Open Access
- 12 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (12) , 5318
Iron Metabolism in the Colorectal Tumor Microenvironment: From Preneoplastic Lesions to Cancer Progression
Colorectal cancer (CRC) is a major global health burden characterized by progressive genetic and metabolic alterations, with iron metabolism being increasingly recognized as a key contributor to tumorigenesis. This review provides an integrated synthesis of current evidence on iron metabolism across the continuum of colorectal cancer development, from preneoplastic lesions to advanced disease. We analyzed data from epidemiological, experimental, and mechanistic studies addressing systemic and cellular iron homeostasis, including the hepcidin–ferroportin axis, as well as iron handling within tumor cells and the tumor microenvironment. Available data indicate that colorectal epithelial cells progressively develop an iron-retentive phenotype, characterized by increased iron uptake and reduced export, leading to expansion of the intracellular labile iron pool. This imbalance contributes to oxidative stress, DNA damage, metabolic adaptation, and activation of oncogenic signaling pathways while also influencing immune responses. However, epidemiological findings on dietary iron and CRC risk remain inconsistent, highlighting the context-dependent nature of iron-related effects. In conclusion, iron metabolism represents a dynamic regulator of CRC progression and a mechanistic framework for understanding stage-specific tumor evolution, although further studies are needed to clarify how iron-dependent pathways differ across colorectal tumor subtypes and microenvironmental contexts.
- 12 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (12) , 5318
Open AccessIron Metabolism in the Colorectal Tumor Microenvironment: From Preneoplastic Lesions to Cancer Progression
Colorectal cancer (CRC) is a major global health burden characterized by progressive genetic and metabolic alterations, with iron metabolism being increasingly recognized as a key contributor to tumorigenesis. This review provides an integrated synthesis of current evidence on iron metabolism across the continuum of colorectal cancer development, from preneoplastic lesions to advanced disease. We analyzed data from epidemiological, experimental, and mechanistic studies addressing systemic and cellular iron homeostasis, including the hepcidin–ferroportin axis, as well as iron handling within tumor cells and the tumor microenvironment. Available data indicate that colorectal epithelial cells progressively develop an iron-retentive phenotype, characterized by increased iron uptake and reduced export, leading to expansion of the intracellular labile iron pool. This imbalance contributes to oxidative stress, DNA damage, metabolic adaptation, and activation of oncogenic signaling pathways while also influencing immune responses. However, epidemiological findings on dietary iron and CRC risk remain inconsistent, highlighting the context-dependent nature of iron-related effects. In conclusion, iron metabolism represents a dynamic regulator of CRC progression and a mechanistic framework for understanding stage-specific tumor evolution, although further studies are needed to clarify how iron-dependent pathways differ across colorectal tumor subtypes and microenvironmental contexts.